wasting (PEW), new infections, long hospital stays, high medical costs, and high mortality. During a 3-month follow-up, acute decompensated cirrhotic patients with high serum PTX 3 / sTWEAK levels had more episodes of unplanned readmission and high 3-month mortality. On multivariate analysis, high PTX 3 /sTWEAK levels and PEW were independent risk factors for high mortality. Conclusion: High serum PTX 3 /sTWEAK levels and PEW are common in cirrhotic patients with acute decompensation. As compared with low serum PTX 3 and sTWEAK cases, cirrhotic patients with high serum PTX 3 /sTWEAK levels a have higher probability of new severe infections, severe sepsis, septic shock, type 1 hepatorenal syndrome, in-hospital, and 3-month follow-up mortalities. Therefore, high serum PTX 3 /sTWEAK levels on hospital admission predict disease severity and case fatality in cirrhotic patients with acute decompensation.
Introduction
A significantly higher percentage of acute decompensated cirrhotic patients develop a bacterial infection either at the time of admission or later during their hospitalization compared with the general population. 1 In advanced cirrhosis, infections are increasingly recognized as major triggers of severe systemic inflammation, renal failure, encephalopathy, multiple organ failure, septic shock, and high mortality.
2e5 Therefore, it is important to find risk factors for organ failure and death in order to help clinicians identify patients at the highest risk that may benefit from early intensified surveillance, prophylaxis, and therapy. 6 C-reactive protein (CRP), the short pentraxin, is primarily produced in the liver and its specificity as a diagnostic and prognostic tool for infection is limited. 6e8 Accordingly, using serum CRP levels in cirrhotic patients with compromised liver function will underestimate the severity of acute infection. Therefore, it is crucial to find better biomarkers for early detection of acute infection in cirrhotic patients. Pentraxin-3 (PTX 3 ) is produced by innate immunity and endothelial cells in response to inflammatory cytokines. PTX 3 has been suggested as a rapid disease activity marker for primary local inflammation. 9, 10 Due to extrahepatic synthesis, PTX 3 levels are believed to be an independent indicator of disease activity produced at sites of inflammation.
11e13 PTX 3 activates complement and innate immunity, hence playing crucial roles in tissue and vascular inflammation. 9 In patients with heart failure and chronic kidney disease, PTX 3 has been reported as an important predictive marker for adverse clinical outcomes. 14, 15 A recent study suggested that a high PTX 3 level on hospitalization predicts severe sepsis and case fatalities in patients with suspected infections. 16 Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily of structurally related cytokines. 17, 18 TWEAK activates the release of inflammatory cytokines and adhesion molecules in inflammatory microenvironments to induce severe tissue injury. 17e19 In hemodialysis patients, high serum TWEAK levels strongly predicted cardiovascular and all-cause mortality. 20 Protein-energy wasting (PEW) is considered as an independent predictor of survival in cirrhotic patients. 21, 22 Interestingly, elevated PTX 3 is associated with PEW in patients with chronic kidney disease and predicted all-cause mortality. 15 Additionally, sTWEAK and PTX 3 are surrogate markers of PEW that induce strong muscle wasting. 15, 23 Acute decompensated cirrhotic patients with infection are characterized by PEW, acute tissue, and vascular inflammation. Taken together, this article aims to assess whether serum PTX 3 and sTWEAK levels are associated with differences in the severity of infection, clinical complications, and short-and long-term mortalities in cirrhosis.
Methods
Detailed methods are provided in the supporting information (see Supplementary material online).
Patients
All consecutive adult 108 patients admitted to our hospital between January 2010 and June 2014 for treatment of an acute decompensation of cirrhosis [ascites, hepatic encephalopathy (HE), bacterial infection, variceal bleeding, and hepatorenal syndrome (HRS)] were studied prospectively. 5, 24 Inclusion criteria were age between 18 years and 80 years and hospitalization due to clinical decompensation of cirrhosis.
Exclusion criteria were: human immunodeficiency virus infection, previous transplantation or any other type of immunodeficiency, steroid treatment, pituitary or adrenal disease, hepatocellular carcinoma, severe chronic heart [New York Heart Association (NYHA) function class III or IV] or pulmonary disease [global initiative for chronic obstructive lung disease (GOLD) III or IV], chronic dialysis, acute respiratory distress syndrome, and refusal of patient to participate. Patients or their relatives, in cases of HE, gave written informed consent to participate in the study which was approved by the Clinical Investigation and Ethics Committee of Taipei Veterans General Hospital. On resolution of HE, informed consent was requested from the patients for continuation of the study.
Additionally, age and sex-matched unrelated 169 controls, who visited our hospital for health check-ups and who had no clinical or biochemical evidence of liver, renal, and cardiovascular disease, were also included as the comparison group in this study.
Serum sTWEAK and PTX 3 measurements
In our study, serum CRP, tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6), PTX 3 , and sTWEAK levels were measured in all cases. Then, the serum PTX 3 /sTWEAK levels were divided into 1 st e4 th quartiles as previously described.
14 The 1 st quartile of serum PTX 3 level was < 11.6 ng/mL (n Z 19); range of 2 nd quartile of serum PTX 3 level was 11.6e15.8 ng/mL (n Z 31); range of 3 rd quartile of serum PTX 3 level was 15.8e25.9 ng/mL (n Z 35); range of 4 th quartile of serum PTX 3 level was > 25.9 ng/mL (n Z 23) whereas the 1 st quartile serum sTWEAK level was < 760 ng/mL (n Z 8); range of 2 nd quartile of serum sTWEAK level was 760e928 ng/mL (n Z 44); range of 3 rd quartile of serum sTWEAK level was 928e1748 ng/mL (n Z 41); and the range of the 4 th quartile of serum sTWEAK level was > 1748 ng/mL (n Z 15) in our study.
The cut-off levels for high and low PTX 3 /sTWEAK levels were determined by the corresponding second tertile levels of acute decompensated cirrhotic patients. In detail, the serum PTX 3 /sTWEAK levels greater than the 66 th percentile were defined as high serum PTX 3 (! 16.6 ng/mL) or sTWEAK (! 1096.7 pg/mL) group as previously suggested. 20 From ongoing studies focusing on exploring various prognostic biomarkers at the regular outpatient department (OPD), we enrolled another small group (n Z 48) of age and sexmatched well-compensated cirrhotic patients with available blood samples for measurement of PTX 3 /sTWEAK levels. The exclusion criteria for these well-compensated cases were the same as our main studied group-cases with acute decompensation.
Protein energy wasting
Protein energy wasting (PEW) was assessed using subjective global nutritional assessment (SGNA) at the time of inclusion, concurrent with the drawing of blood samples for routine hematological, biochemical, and coagulation studies. 21, 22 PEW was defined as SGNA score of > 1 (2e4), and patients who met these criteria were grouped together as malnourished patients. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.
21,22

Endpoints
New clinical events (including bacterial infections, gastrointestinal bleeding, hepatic encephalopathy, and HRS) developed during hospitalization and up to 3 months, but not those diagnosed at inclusion, were included in the analysis of clinical outcome. In-hospital and 3-month mortality, causes of deaths, total length of hospital stay (LOS), hospital medical costs, successive unplanned hospitalization including reasons for admission, applied therapy, and diagnosis at discharge of enrolled patients were recorded. Severity of infections [systemic inflammatory response syndrome (SIRS), severe sepsis, and septic shock] occurring during the 3-month follow-up was also recorded. 25 
Hospital medical cost estimation
Hospital medical costs charged by Taiwan's National Health Insurance Administration (NHIA) include institutional services, prescription drugs used, diagnostic tests carried out, physician encounters, nursing, and other health services costs. High medical cost is defined as > 1.5-fold of medical cost than the average cost of low serum PTX 3 and sTWEAK group in cirrhotic patients.
Statistical analysis
Continuous variables were compared by the Student t test or by the ManneWhitney U test when indicated. Discontinuous variables were compared by the Chi-square test. Survivals were obtained by the KaplaneMeier method and compared using the log-rank test. Calculations were performed with the SPSS version 11.0 (SPSS Inc., Chicago, IL, USA). Differences were considered significant at p < 0.05. Results are given as mean AE standard deviation.
Results
Baseline characteristics of study population
In comparison with unrelated healthy controls, serum PTX 3 / sTWEAK levels were already significantly increased in wellcompensated cirrhotic patients (Table 1) . Significantly, higher (PTX 3 ) and (sTWEAK) were observed in acute decompensated cirrhotic patients than control individuals and well-compensated cirrhotic patients (Table 1) . Additionally, cirrhotic patients with higher serum PTX 3 (! 16.6 ng/mL)/sTWEAK (! 1096.7 pg/mL) levels had a longer length of hospital stay and more hospitalization medical costs than their counterparts (Table 2) . We found that 23 of our 33 (70%) hepatitis B virus (HBV)-and none of our 36 (0%) hepatitis C virus (HCV)-induced cirrhotic patients received antiviral therapy at inclusion. Notably, serum PTX 3 or sTWEAK levels are similar between our enrolled acute decompensated cirrhotic patients with (n Z 23) and without (n Z 46) antiviral therapy (PTX 3 : 18.9 AE 2.2 ng/mL vs. 20.13 AE 1.5 ng/mL; sTWEAK: 1563.39 AE 71.86 pg/mL vs. 1487.69 AE 55.67 pg/mL).
Serum PTX 3 and sTWEAK levels are closely correlated with PEW Significantly, higher serum PTX 3 and sTWEAK levels were observed in acute decompensated cirrhotic patients with PEW than their counterparts ( Figure 1A ). In particular, the percentage of PEW was significantly higher in high PTX 3 and sTWEAK groups than the corresponding low PTX 3 and sTWEAK groups (Table 2) . Additionally, a significant correlation was noted between the PTX 3 and SGNA score as well as between the sTWEAK and SGNA score of acute decompensated cirrhotic patients (Table 3) . Serum PTX 3 and sTWEAK levels are closely correlated with high levels of inflammatory mediators Serum IL-6 and TNF-a levels were significantly higher in acute decompensated cirrhotic patients belonging to high PTX 3 and sTWEAK groups than their counterparts (Table 2) .
Significantly, a positive correlation was noted between PTX 3 and IL-6 as well as between sTWEAK and IL-6 (Table 3) . Nonetheless, a significantly higher serum CRP level was only noted in the high PTX 3 group than the low PTX 3 group. Meanwhile, the PTX 3 significantly positively correlated with serum TNF-a and CRP levels (Table 3) . Differentially, the difference of serum CRP levels between high sTWEAK and low sTWEAK groups did not reach CRP Z C-reactive protein; IL-6 Z interleukin-6; PTX 3 Z pentraxin-3; SGNA Z subjective global nutritional assessment; sTWEAK Z soluble TNF-like weak inducer; TNF-a Z tumor necrosis factor-a.
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statistical significance in acute decompensated cirrhotic patients. The sTWEAK was not significantly correlated with serum TNF-a and CRP levels ( Table 3) .
Association between serum PTX 3 /sTWEAK levels and severity of infection during admission
More acute decompensated cirrhotic patients with high serum PTX 3 and sTWEAK levels met the criteria of SIRS for inclusion in our study (Table 2 ). In subgroup analysis according to the infection status, significantly higher PTX 3 and sTWEAK levels were presented in acute decompensated cirrhotic patients with SIRS or concurrent infection than healthy controls; whereas serum PTX 3 levels were not different between acute decompensated cirrhotic patients without SIRS or infection and healthy controls ( Figure 2A ). In acute decompensated cirrhotic patients, more severe infection, such as sepsis, severe sepsis, and septic shock, was associated with higher serum PTX 3 levels (Figure 2A ). By contrast, even without the presence of SIRS or concurrent infection, the serum sTWEAK level was significantly increased in acute decompensated cirrhotic patients than healthy controls. However, the sequential elevation of sTWEAK levels along with the increased infectious severity was not apparent in our study group ( Figure 2B ).
Association between serum PTX 3 /sTWEAK levels and new clinical events
Compared with acute decompensated cirrhotic patients with lower serum PTX 3 levels (< 16.6 ng/mL), those with a higher PTX 3 level suffered from significantly more events of bacterial infection, including spontaneous bacterial peritonitis (SBP), severe sepsis, septic shock, and type 1-HRS during hospitalization (Table 4 ). The incidence of such clinical events at 3 months of follow-up was also significantly higher in acute decompensated cirrhotic patients with higher serum levels of PTX 3 . Likewise, acute decompensated cirrhotic patients with higher serum sTWEAK levels (! 1096.7 pg/mL) had significantly more incidence of bacterial infection, SBP, severe sepsis, and septic shock during hospitalization. At 3 months of follow-up, the incidence of such clinical events was significantly higher in acute decompensated cirrhotic patients with higher serum sTWEAK level, as well (Table 4) . Significantly, a higher clinical event-free rate was noted in the low serum PTX 3 / sTWEAK groups than its corresponding groups after 3 months follow-up ( Figures 1B and 1C) . In subgroup analysis according to the respective quartiles of serum PTX 3 and sTWEAK levels, the relative risk for clinical events, including severe sepsis, septic shock, and type 1-HRS, at 3 months of follow-up was significantly higher in acute decompensated cirrhotic patients with the highest (4 th quartile) serum PTX 3 and sTWEAK levels than those with the lowest (1 st quartile) corresponding levels ( Figure 1D ).
Risk factors at inclusion for new clinical complications and mortality of acute decompensated cirrhotic patients
On univariate analysis, high PTX 3 and sTWEAK levels, presence of PEW, septic shock, and hyponatremia were significantly related to unplanned readmission and high mortality during the 3-month follow-up (Table 5) .
On multivariate analysis, both high serum PTX 3 and sTWEAK levels were associated with increased risks of inhospital and 3-month mortality (Table 6 ). Besides, PEW increased the risks of mortality, unplanned readmission, and high medical costs during hospitalization.
Discussion
In response to bacterial infection, cirrhotic patients have pronounced inflammatory response with elevated systemic pyrogenic cytokines IL-6 and TNF-a concentrations. 26 As a consequence, SIRS can be found in up to 67% of cirrhotic patients with bacterial infections compared with 37% of patients without, making sepsis a common complication of advanced cirrhosis. 27 Therefore, a higher percentage of our cirrhotic patients complicated with SIRS and sepsis have high serum PTX 3 and sTWEAK levels. Clinically, a higher percentage of decompensated cirrhotic patients met SIRS criteria due to hyperdynamic circulation-related tachycardia or tense ascites-related hyperventilation. However, these patients might be finally classified as having sterile SIRS if negative for any inflammation and infection after careful surveys. Therefore, it is important to precisely detect early conditions that are serious rather than sterile SIRS in order to give great beneficial management to patients at the right time point.
In cirrhotic patients, serum concentrations of inflammatory marker IL-6 and CRP are positively correlated with risk of organ failure and increased short-term mortality. 7, 27, 28 Interestingly, a significant correlation was noted between serum IL-6 and CRP levels supported previous reports of IL-6 as a potent inducer of CRP. 29 In acute decompensated cirrhotic patients with suspected infection, high serum IL-6 and TNF-a had been found to correlate with increased in-hospital episodes of bacterial infection, shortterm reinfection, and 1-year mortality. 30 However, neither IL-6 nor TNF-a determine the mortality of our acute decompensated cirrhotic patients. These discrepancy results might come from different studied groups between previous studies and our current study. 30 In multivariate analysis, the ChildePugh and model for end stage liver disease (MELD) scores did not predict mortality in our study. These results indicated that factors other than severity of cirrhosis contributed to the mortality of acute decompensated cirrhotic patients. In fact, a previous study reported that MELD score is not a perfect prognostic tool and some decompensated cirrhotic patents may be misclassified as a low risk group. 31 Hyponatremia is reported to be associated with increased severity of complications and risk of mortality in cirrhotic patients. 32 Therefore, it is reasonable to find in our study that hyponatremia is associated with high 3-month mortality in our acute decompensated cirrhotic patients.
In cirrhosis, PEW is due to chronic inflammation, reduction in oral intake (for various causes), increased protein catabolism, insufficient synthesis, malabsorption, and maldigestion associated with portal hypertension. 33 Worse PEW can lead to ascites, encephalopathy, hepatorenal syndrome, septic complications, poorer quality life, a reduced life span, and death in cirrhosis. 21, 22, 33 Using clinical information to determine nutritional status, SGNA score accounting for recent weight loss or gain, has been successfully applied to cirrhotic patients to predict the outcome after liver transplantation. 21 In our cirrhotic patients with acute decompensation, a strong correlation was noted between SGNA and serum sTWEAK levels. It has been reported that TWEAK induces proinflammatory cytokine production. 34 Furthermore, proinflammatory cytokines stimulate the PTX 3 production. 35 In other words, the regulation of serum PTX 3 production by sTWEAK is mediated by proinflammatory cytokines. This cross-interaction between sTWEAK and PTX 3 was further confirmed by simultaneous elevations of serum sTWEAK and PTX 3 in patients with chronic kidney disease 36 and acute decompensated cirrhotic patients in our study.
Concomitant renal failure is a major determinant for mortality of admitted cirrhotic patients. 37 Cirrhotic patients with acute kidney injury (AKI) develop type 1-HRS, which reduces survival presumably by superimposing inflammation. 38 Aggressive treatment with high-dose intravenous albumin substitution for type 1-HRS seems a legitimate approach to reduce mortality of admitted cirrhotic patients. Estimation of medical costs in our study is based on the public connected database of our medical center with National Health Insurance Administration (NHIA) which includes length of hospital stay and medical costs. In Taiwan, albumin is expensive and most cirrhotic patients cannot afford the economic burden for adequate doses of intravenous albumin infusion for type 1-HRS. For admitted cirrhotic patients with the diagnosis of type 1-HRS, NHIA pays for their albumin-related medical costs. Undoubtedly, the hospitalization medical costs for cirrhotic patients with type 1-HRS must be remarkably higher than those without type 1-HRS. Therefore, it is reasonable to find in our study that cirrhotic patients with type 1-HRS have high mortality and hospitalization medical costs.
In either HBV-or HCV-induced cirrhotic patients, our initial comparison data indicated that presence of antiviral therapy at inclusion did not modify the serum PTX 3 /sTWEAK levels of enrolled acute decompensated cirrhotic patients. However, the small and imbalance of the group size (n Z 23 vs. n Z 46) between our acute decompensated cirrhotic patients with and without using oral nucleotide analogues might affect the evaluation of the impact of antiviral therapy on the serum PTX 3 /sTWEAK levels. Therefore, further well-designed studies with large and balance sample size is mandatory to elucidate the effect of antiviral therapy on the serum PTX 3 /sTWEAK levels of acute decompensated cirrhotic patients.
In our study, with a single determination of serum PTX 3 and sTWEAK levels, we cannot take into account any variation that may have occurred over time. However, this is not a major limitation because other inflammation and laboratory markers were measured only once in this study.
Uusitalo-Seppälä et al 16 reported the role of high serum PTX 3 level in emergency room patients with suspected infections whereas our study reported the role of high serum PTX 3 and sTWEAK levels in admitted acute decompensated cirrhotic patients. Uusitalo-Seppälä et al 16 defined severe sepsis as severe infection whereas severe infection in our study included severe sepsis and septic shock. The endpoints of Uusitalo-Seppälä et al 16 study are 28-day mortality and severe sepsis whereas our studying end points are new in-hospital clinical events, in-hospital and 3-month mortality, total length of hospital stay (LOS), high hospitalization medical costs, and unplanned readmission rates.
Conclusively, the novelties raised from this study include high serum PTX 3 and sTWEAK levels are associated with PEW, high hospitalization medical costs, and mortality in cirrhotic patients with acute decompensation. Additionally, high serum sTWEAK levels and presence of PEW contributed to the high incidence of unplanned readmission rates in acute decompensated cirrhotic patients. Therefore, measurement of serum PTX 3 and sTWEAK levels provide a new strategy to more aggressive treatments for high risk groups. Therefore, infection prevention (vaccinations, hygiene, and nutrition), antimicrobial deescalation strategies, and surveillance for early signs of organ dysfunction are required to reduce the burden associated with new clinical events and mortality in admitted high-risk cirrhotic patients with acute decompensation.
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